PIK3CD and activated PI3K-delta syndrome: In a cohort of 53 patients with APDS due to PIK3CD mutations described by Coulter et al, 6 patients received sirolimus for benign lymphoproliferation, and 5 of 6 (83%) patients had clinical improvement, although notably, sirolimus had to be discontinued in one patient due to intolerable side effects (46).